Reiter Selina, Schroeder Christopher, Broche Julian, Sinnberg Tobias, Bonzheim Irina, Süsskind Daniela, Flatz Lukas, Forschner Andrea
Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Institute of Medical Genetics and Applied Genomics, University Hospital of Tübingen, Tübingen, Germany.
Front Oncol. 2023 May 3;13:1167791. doi: 10.3389/fonc.2023.1167791. eCollection 2023.
Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM.
转移性葡萄膜黑色素瘤（UM）是一种罕见的黑色素瘤，在病因、预后、驱动基因突变、转移模式以及对免疫检查点抑制剂（ICI）的低反应率等方面与皮肤黑色素瘤不同。最近，一种双特异性gp100肽-HLA导向的CD3 T细胞衔接器tebentafusp已被批准用于治疗HLA-A*02:01转移性或不可切除的UM。虽然治疗方案复杂，需要每周给药并密切监测，但反应率有限。关于tebentafusp治疗失败后UM联合ICI治疗的数据很少。在本病例报告中，我们介绍了一名转移性UM患者，该患者在接受tebentafusp治疗时首先出现广泛进展，但随后对联合ICI治疗有出色反应。我们讨论了可能的相互作用，这些相互作用可以解释晚期UM患者在接受tebentafusp预处理后对ICI的反应性。
